Scholarlink

<p>Elevated cholesterol increases risk of diseases such as heart disease, chronic kidney disease and diabetes and early detection and diagnosis is desirable to enable preventative intervention. This study seeks to elucidate genetic factors affecting low-density lipoprotein cholesterol (LDL-C) levels in blood, enabling development of personalised strategies for lipid management and cardiovascular disease prevention. GenePy, a gene pathogenicity scoring tool, condenses genetic variant data into a single burden score for both individuals and genes. GenePy scores were evaluated across all genes to assess their association with blood cholesterol levels, excluding participants on cholesterol-lowering medications. Nonparametric tests analysed the relationship between GenePy scores and cholesterol levels in those aged &lt; 60 years and ≥ 60 years. GenePy was effective in identifying <i>PCSK9</i>, <i>APOE</i>, and <i>LDLR</i> as the genes most critically influencing plasma cholesterol at a population level. Of note, the strongest genetic effect observed was a <i>protective</i> loss of function effect in the <i>PCSK9</i> gene. Novel significant signals driving blood LDL-C levels that are common to both age groups include: <i>BPIFB6</i> that has a role in lipid binding and transport; <i>FAIM</i> that has a role in regulation of lipogenesis, <i>SLAMF9</i> previously implicated in macrophage cholesterol loading; <i>CLU</i>—a component of HDL; <i>SAA1</i> with a known role in cholesterol homeostasis. A gene-based analysis integrating common, rare, and private variations identifies genes influencing blood LDL-C levels. Developing effective polygenic risk scores requires a comprehensive understanding of genetic factors affecting cholesterol to improve prediction and personalise treatment plans.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of genetic biomarkers of blood cholesterol levels using whole gene pathogenicity modelling

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月6日

查看全文
  • Sharon Sunny,
  • Guo Cheng,
  • Joshua Haria,
  • Iman Nazari,
  • Jagmohan Chauhan,
  • Sarah Ennis

摘要

Elevated cholesterol increases risk of diseases such as heart disease, chronic kidney disease and diabetes and early detection and diagnosis is desirable to enable preventative intervention. This study seeks to elucidate genetic factors affecting low-density lipoprotein cholesterol (LDL-C) levels in blood, enabling development of personalised strategies for lipid management and cardiovascular disease prevention. GenePy, a gene pathogenicity scoring tool, condenses genetic variant data into a single burden score for both individuals and genes. GenePy scores were evaluated across all genes to assess their association with blood cholesterol levels, excluding participants on cholesterol-lowering medications. Nonparametric tests analysed the relationship between GenePy scores and cholesterol levels in those aged < 60 years and ≥ 60 years. GenePy was effective in identifying PCSK9, APOE, and LDLR as the genes most critically influencing plasma cholesterol at a population level. Of note, the strongest genetic effect observed was a protective loss of function effect in the PCSK9 gene. Novel significant signals driving blood LDL-C levels that are common to both age groups include: BPIFB6 that has a role in lipid binding and transport; FAIM that has a role in regulation of lipogenesis, SLAMF9 previously implicated in macrophage cholesterol loading; CLU—a component of HDL; SAA1 with a known role in cholesterol homeostasis. A gene-based analysis integrating common, rare, and private variations identifies genes influencing blood LDL-C levels. Developing effective polygenic risk scores requires a comprehensive understanding of genetic factors affecting cholesterol to improve prediction and personalise treatment plans.